Altrius Capital Management Inc Buys 1,685 Shares of Sanofi (NASDAQ:SNY)

Altrius Capital Management Inc lifted its position in shares of Sanofi (NASDAQ:SNY) by 1.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 160,733 shares of the company’s stock after purchasing an additional 1,685 shares during the period. Sanofi accounts for approximately 2.0% of Altrius Capital Management Inc’s portfolio, making the stock its 11th largest position. Altrius Capital Management Inc’s holdings in Sanofi were worth $7,799,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cascade Investment Advisors Inc. increased its position in shares of Sanofi by 4.7% during the first quarter. Cascade Investment Advisors Inc. now owns 34,359 shares of the company’s stock valued at $1,670,000 after buying an additional 1,535 shares during the period. Vestal Point Capital LP purchased a new position in shares of Sanofi in the 4th quarter valued at approximately $14,919,000. Dynamic Advisor Solutions LLC boosted its position in shares of Sanofi by 39.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock valued at $2,780,000 after purchasing an additional 16,117 shares in the last quarter. Manning & Napier Advisors LLC purchased a new stake in Sanofi in the second quarter worth $13,725,000. Finally, Mount Yale Investment Advisors LLC raised its holdings in Sanofi by 44.3% in the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after purchasing an additional 12,806 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of recent research reports. Argus upped their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 11th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Sanofi currently has an average rating of “Hold” and an average price target of $57.50.

Sanofi Stock Performance

Shares of SNY stock opened at $57.47 on Thursday. The company has a market capitalization of $145.56 billion, a price-to-earnings ratio of 28.88, a price-to-earnings-growth ratio of 1.60 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a one year low of $42.63 and a one year high of $58.97. The company’s 50-day moving average is $54.08 and its 200 day moving average is $50.35.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Sell-side analysts expect that Sanofi will post 4.25 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.